TY - JOUR
A2 - S nchez Garc a, Fj
AU - Zhang, Huanchang
AU - Duan, Yunfeng
AU - Cai, Feng
AU - Cao, Demin
AU - Wang, Lei
AU - Qiao, Zhenyi
AU - Hong, Qing
AU - Li, Nan
AU - Zheng, Yuanrong
AU - Su, Miya
AU - Liu, Zhenmin
AU - Zhu, Baoli
PY - 2022
DA - 2022/11/16
TI - Next-Generation Probiotics: Microflora Intervention to Human Diseases
SP - 5633403
VL - 2022
AB - With the development of human genome sequencing and techniques such as intestinal microbial culture and fecal microbial transplantation, newly discovered microorganisms have been isolated, cultured, and researched. Consequently, many beneficial probiotics have emerged as next-generation probiotics (NGPs). Currently, “safety,” “individualized treatment,” and “internal interaction within the flora” are requirements of a potential NGPs. Furthermore, in the complex ecosystem of humans and microbes, it is challenging to identify the relationship between specific strains, specific flora, and hosts to warrant a therapeutic intervention in case of a disease. Thus, this review focuses on the progress made in NGPs and human health research by elucidating the limitations of traditional probiotics; summarizing the functions and strengths of Akkermansia muciniphila, Faecalibacterium prausnitzii, Bacteroides fragilis, Eubacterium hallii, and Roseburia spp. as NGPs; and determining the role of their intervention in treatment of certain diseases. Finally, we aim to provide a reference for developing new probiotics in the future.
SN - 2314-6133
UR - https://doi.org/10.1155/2022/5633403
DO - 10.1155/2022/5633403
JF - BioMed Research International
PB - Hindawi
KW -
ER -